RESEARCH ARTICLE

A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002–2011

Lycely del C. Sepúlveda-Torres[1]*, Lavanya Rishishwar[2,3,4], Maria Luisa Rogers[5], Eddy Ríos-Olivares[1], Nawal Boukli[1], I. King Jordan[2,3,4], Luis A. Cubano[1]

1 Department of Microbiology and Immunology, Universidad Central del Caribe, Bayamón, Puerto Rico, United States of America, 2 School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, United States of America, 3 PanAmerican Bioinformatics Institute, Cali, Valle del Cauca, Colombia, 4 Applied Bioinformatics Laboratory, Atlanta, Georgia, United States of America, 5 Natural Sciences Department, Sacred Heart University, San Juan, Puerto Rico, United States of America

* lycely.sepulveda@uccaribe.edu, lycely@gmail.com

Abstract

Puerto Rico has one of the highest rates of HIV/AIDS seen for any US state or territory, and antiretroviral therapy has been a mainstay of efforts to mitigate the HIV/AIDS public health burden on the island. We studied the evolutionary dynamics of HIV-1 mutation and antiretroviral drug resistance in Puerto Rico by monitoring the population frequency of resistance-associated mutations from 2002 to 2011. Whole blood samples from 4,475 patients were analyzed using the TRUGENE HIV-1 Genotyping Kit and OpenGene DNA Sequencing System in the Immunoretrovirus Research Laboratory at Universidad Central del Caribe. Results show that 64.0% of female and 62.9% of male patients had HIV-1 mutations that confer resistance to at least one antiretroviral medication. L63P and M184V were the dominant mutations observed for the protease (PRO) and reverse transcriptase (RT) encoding genes, respectively. Specific resistance mutations, along with their associated drug resistance profiles, can be seen to form temporal clusters that reveal a steadily changing landscape of resistance trends over time. Both women and men showed resistance mutations for an average of 4.8 drugs over the 10-year period, further underscoring the strong selective pressure exerted by antiretrovirals along with the rapid adaptive response of HIV. Nevertheless, both female and male patients showed a precipitous decrease for overall drug resistance, and for PRO mutations in particular, over the entire course of the study, with the most rapid decrease in frequency seen after 2006. The reduced HIV-1 mutation and drug resistance trends that we observed are consistent with previous reports from multi-year studies conducted around the world. Reduced resistance can be attributed to the use of more efficacious antiretroviral drug therapy, including the introduction of multi-drug combination therapies, which limited the ability of the virus to mount rapid adaptive responses to antiretroviral selection pressure.

Introduction

Since the beginning of the HIV/AIDS epidemic through April 2016, a total of 47,722 new cases have been confirmed in Puerto Rico, 10,927 of which were diagnosed in the 10-year period from 2002 to 2011 [1]. Official statistics compiled by the US Centers for Disease Control and Prevention (CDC) underscore the extremely high public health burden imposed by HIV/ AIDS in Puerto Rico. The estimated HIV diagnosis rate for adolescents and adults was 29.5 per 100,000 inhabitants in 2002 and 24.0 in 2011, ranking Puerto Rico as the 5th and 7th highest out of 56 US states and territories for those years [2, 3]. Almost 75% of the epidemic is concentrated in the metropolitan area of San Juan/Carolina/Caguas, which is the most populated region in Puerto Rico. San Juan was ranked as the 9th highest metropolitan area in the US for new HIV infections in 2002, with an HIV diagnosis rate of 35.5, and 13th in the nation in 2011, with a diagnosis rate of 26.6 [2, 3].

The introduction of highly active antiretroviral therapy (HAART) into clinical practice in the late 1990s, coupled with early diagnosis and treatment of HIV infection, led to dramatic reductions in HIV morbidity and mortality, better health outcomes for infected individuals and reduced transmission of HIV to partners [4–6]. From the introduction of antiretroviral therapy until 2010, the annual number of deaths in the US due to AIDS dropped by 85%, including a 14% decrease between 2009 and 2010 alone [7, 8]. Nevertheless, Hispanics/Latinos living in Puerto Rico and on the mainland remain at significantly greater risk for delayed diagnosis of HIV and AIDS compared to non-Hispanic whites, which greatly compromises their access to effective care and treatment [9, 10]. Accordingly, individuals born in Puerto Rico have twice the risk of HIV-related deaths than US-born patients and are even at a higher risk of mortality compared to other Hispanic populations [11, 12]. Vital statistics reported for the testing period covered in this study place AIDS as the 13th leading cause of death for Puerto Ricans living on the island and 17th for Hispanics living in the mainland [13, 14].

Guidelines for the use of antiretroviral agents in HIV-1 infected adolescents and adults call for personalized treatments, whereby specific medications are selected based on the predicted resistance profile for the viral mutation(s) present in the patient, along with other considerations related to comorbidities, dosing frequency and burden, adverse drug interactions, and toxic effects [15, 16]. Current HIV/AIDS treatment protocols call for the essential viral genes that encode for the protease (PRO) and reverse transcriptase (RT) proteins to be sequenced and analyzed in order to detect mutations that are known to confer antiretroviral drug resistance, thereby allowing a suitable combination of antiretroviral drugs to be prescribed. The Universidad Central del Caribe (UCC) provided HIV genome sequencing and drug resistance analysis services for this purpose in Puerto Rico from 2000 to 2011, yielding a unique and valuable data source for research on the evolutionary dynamics of HIV-1 drug resistance on the island. While the UCC HIV-1 antiretroviral drug resistance data for individual years has been published elsewhere [17–19], prior to this time we had yet to attempt a multi-year analysis of resistance trends in Puerto Rico. For the current study, we took a data analysis approach to examine the changing prevalence of HIV-1 resistance-associated mutations in Puerto Rico over the 10-year period from 2002 to 2011. The previously published differences in viral mutations and drug resistance levels between men and women for individual years did not remain significant when the cumulative 10-year dataset was analyzed. Nevertheless, our statistical analysis of HIV-1 resistance mutations over this time frame revealed a number of clear dynamic trends, including a sharp reduction in the frequency of drug resistance mutations over the last 5 years of the 10-year span.

Fig 1. Cohort sample analysis and HIV-1 genotyping workflow used for the study.

Materials and methods

HIV-1 genotyping

HIV-1 genotypes were obtained from 1,397 female, 2,581 male and 497 anonymous HIV-1 infected patients who were referred by their primary care physicians to the Immunoretrovirus Research Laboratory at Universidad Central del Caribe from 2002 to 2011. The samples were analyzed using the protocol illustrated in Fig 1 after the IRB Director at Universidad Central del Caribe deemed the research exempt from the human subjects in research regulations. Whole blood was collected in tubes containing ethylenediaminetetraacetic acid (EDTA) as anticoagulant, followed by plasma separation and storage at -80˚C. HIV-1 viral RNA was extracted using the QIAGEN QIAamp Viral RNA Mini Kit (QIAGEN, Valencia CA) as previously described [19]. RNA samples were analyzed with the TRUGENE HIV-1 Genotyping Kit and OpenGene DNA Sequencing System equipped with a proprietary interpretative algorithm that infers resistance to specific antiretroviral drugs from the observed mutations based on prior knowledge (Siemens Healthcare Diagnostics, Tarrytown, NY).

Quantitative analysis of HIV-1 mutations and drug resistance trends

Information on HIV-1 drug resistance profiles and mutations was taken from de-identified patient TRUGENE HIV-1 Genotyping Kit resistance reports and used to create three databases for (1) drug resistance profiles, (2) protease (PRO) gene mutations, and (3) reverse transcriptase (RT) gene mutations (Fig 1). Patient-isolated viral nucleic acids were screened for resistance to 26 HIV drugs based on 104 PRO mutations and 62 RT mutations. Each database contained individual patient binary presence/absence scores for all the drug resistance profiles and mutations screened during the 2002 to 2011 period. Gender was the only demographic information provided by patients and was included as metadata in the databases. Summary statistics on the overall prevalence of drug resistance and HIV-1 mutations were calculated from the three patient databases to generate the data shown in Fig 2. The statistical significance

(A)

(B)

Fig 2. Observed levels of antiretroviral resistance-associated mutations in Puerto Rico from 2002 to 2011. (A) Drug resistance and mutation frequencies recorded by gender. **(B)** Percentages of individuals seen for the most commonly observed antiretroviral drug resistance and the most frequent mutations in the protease (PRO) and reverse transcriptase (RT) genes.

https://doi.org/10.1371/journal.pone.0177452.g002

of gender differences between drug resistance and mutation trends was tested using the Fisher's exact test. The resulting *P*-values were adjusted via the false discovery rate, calculated using the Benjamini-Hochberg procedure, as a correction for multiple statistical tests.

Additional statistical analyses of the databases were done to compare the dynamics of the drug resistance profiles and HIV-1 mutations for the PRO and RT genes over time. For each drug, the annual drug resistance fraction (d_{res}) was calculated as the number of individuals who tested positive for drug resistance for a given year (n_{res}^i) normalized by the total number of individuals screened that year (n_{tot}^i):

$$d_{res} = n_{res}^i / n_{tot}^i \qquad (1)$$

In order to compare the year-to-year dynamics of resistance between different drugs, an additional calculation was performed to yield normalized drug resistance fractions ($\widehat{d_{res}}$). For each drug, the annual d_{res} values were normalized by the maximum value ($\max(d_{res})$) over all years for that drug.

$$\widehat{d_{res}} = d_{res} / \max(d_{res}) \qquad (2)$$

For each patient, the annual patient drug resistance fraction (p_{res}) was computed as the number of drugs for which the patient was found to be resistant in a given year (n_{res}^d) normalized by

the total number of drugs screened for that patient (n_{tot}^d).

$$p_{res} = n_{res}^d / n_{tot}^d \tag{3}$$

In order to compare the year-to-year dynamics of patient drug resistance, the average values for annual patient drug resistance fractions were calculated. This was done for all patients as well as separately for males and females.

$$\overline{p_{res}} = \sum p_{res} / n_{tot}^i \tag{4}$$

The annual dynamics of HIV-1 resistance mutations in PRO and RT were calculated identically as described above for the normalized drug resistance fractions (Eqs 1 and 2). In the case of the PRO and RT mutations, the calculations were made based on the number of individuals who tested positive for a given mutation in a given year (n_{mut}^i) normalized by the total number of individuals tested that year (n_{tot}^i).

$$PRO_{mut} = n_{mut}^i / n_{tot}^i \tag{5}$$

$$\widehat{PRO_{mut}} = PRO_{mut} / \max(PRO_{mut}) \tag{6}$$

$$RT_{mut} = n_{mut}^i / n_{tot}^i \tag{7}$$

$$\widehat{RT_{mut}} = RT_{mut} / \max(RT_{mut}) \tag{8}$$

Only the most common 49 PRO and 51 RT mutations were selected for subsequent analysis, as the remaining low frequency mutations cannot be accurately analyzed with respect to any dynamic trends over time.

Results

Overview of HIV-1 drug resistance and mutation trends in Puerto Rico from 2002 to 2011

HIV-1 genotypes and associated drug resistance profiles were characterized for 4,475 patients over a 10-year period in Puerto Rico using the approach shown in Fig 1, as described in the Materials and Methods section. S1 Table contains a complete list of the counts of individuals showing protease (PRO) and reverse transcriptase (RT) mutations, along with their associated drug resistance counts, broken down by gender and year. The most commonly observed mutations and their associated antiretroviral resistant profiles are summarized in Fig 2. HIV-1 virus strains harboring at least one antiretroviral drug resistance-associated mutation were found in 64.0% of women and 62.9% of men; both women and men showed resistance to an average of ~4.8 drugs over the 10-year period (Fig 2). 89.6% of women and 91.8% of men were infected with strains containing at least one PRO gene mutation, with corresponding resistance to an average of 3.3 PRO inhibitor drugs for women and 3.4 for men. 63.9% of women had at least one RT gene mutation compared to 59.9% of men, with corresponding resistance to an average of 2.1 RT medications for both. We checked for gender differences in drug resistance and mutations across each individual year using the Fisher's exact test. After correcting for multiple statistical tests using the false discovery rate, no drugs or mutations showed statistically significant gender differences for any single year or for the entire 10-year period.

HIV-1 antiretroviral drug resistance trends

HIV-1 resistance levels to antiretroviral drugs were inferred from PRO and RT gene mutations characterized using the TRUGENE HIV-1 Genotyping Kit as described in the Materials and Methods section. Hierarchical clustering and presentation of normalized drug resistance levels revealed two distinct time periods that overlap slightly around 2007, each of which is characterized by peak resistance levels to different sets of drugs (Fig 3). We did not observe any clear relationship between the class of action of the antiretroviral drugs and the two peak time periods. The highest antiretroviral drug resistance levels over the 10-year period were observed for Zalcitabine (59.0%), Didanosine (58.0%) and Lamivudine (51.4%) (Figs 2 and 3), whereas Tipranavir + ritonavir (TPV/r), Darunavir + ritonavir (DRV/r) and Etravirine (ETR) showed the lowest levels of resistance.

Protease (PRO) resistance-associated mutation trends

We performed hierarchical clustering of normalized PRO mutation frequencies for the 49 most common mutations in order to visualize their evolutionary dynamics. PRO mutation trends were found to be highly dynamic over the 10-year time period and can be resolved into five distinct mutation groups based on the hierarchical clustering (Fig 4). Class 1 had peak frequencies prior to 2007 followed by a steady and gradual decrease through the end of the 10-year period. Class 2 shows a similar trend as seen for class 1 with the exception of the re-emergence of 2 mutations in 2010 and 6 mutations in 2011. Class 3 peak frequencies were observed around 2006–2007, whereas class 4 mutations were virtually absent prior to that time and peaked afterwards. Class 4 mutations are also characterized by their relatively high average frequency over this second time period. Class 5 shows the most internal divergence with 4 mutations that peaked markedly in one year, whereas the remaining mutations are observed at uniformly low to moderate frequencies across all years, including the M36I mutation that stands out by virtue of its sustained moderate frequency level. The 3 most prevalent HIV-1 resistance-associated mutations for PRO were L63P (73.9%), V77I (45.2%) and I13V (34.2%), whereas I50L, I50V and K20I were the least abundant mutations recorded during the 10-year period (Figs 2 and 4).

## Reverse transcriptase (RT) resistance-associated mutation trends

We also performed hierarchical clustering of normalized RT mutation frequencies for the 51 most common mutations in order to visualize their evolutionary dynamics. RT mutation trends are similarly dynamic, and even more variable across years, compared to what was observed for PRO mutations (Fig 5). RT mutations can also be grouped into five classes using hierarchical clustering; although, the dynamics among these are slightly different compared to those observed for PRO. Overall, there is a higher frequency of RT mutations early in the time period followed by a subsequent decline in frequency. This pattern is exemplified by Class 1 and Class 2, both of which were highly frequent until 2007, followed by a decline in frequencies thereafter. These two classes also contain the mutations that are seen in the highest frequency across the entire time period. The remaining three classes all show marked mutation peaks in a single year coupled with relatively low frequency levels over the rest of the period. Class 4 mutations peak in 2011 and show moderate frequencies for the rest of the period. Class 5 has exclusive mutation frequency peaks in the first two years of the study (2002–2003), followed by low frequencies over the rest of the period. The RT mutations with the highest average frequencies were M184V (47.9%), K103N (42.6%) and M41L (34.2%) (Figs 2 and 5); the three least common RT mutations over the 10-year period were K103T, Y188C and P236L (S1 Table).

Fig 3. Trends in HIV-1 drug resistance levels in Puerto Rico from 2002 to 2011. The names of the antiretroviral drugs are color-coded with respect to their class of action as shown in the key in the middle of the figure. **(A)** Normalized drug resistance frequencies, color-coded as shown in the key, are shown for the drugs analyzed here over the 2002–2011 period. White boxes indicate an absence of resistance mutations for a drug in any given year. Normalized drug resistance fraction profiles are grouped using hierarchical clustering, revealing two clusters with distinct peak resistance periods. **(B)** The maximum observed resistance fractions are shown for all drugs alongside **(C)** box-plot distributions of the maximum observed resistance fractions.

https://doi.org/10.1371/journal.pone.0177452.g003

Fig 4. Trends in HIV-1 protease mutations in Puerto Rico from 2002 to 2011. (A) Normalized protease (PRO) mutation frequencies, color-coded as shown in the key, are shown for the 2002–2011 period. White boxes indicate an absence of PRO resistance mutations in any given year. PRO mutation frequency profiles are grouped using hierarchical clustering, revealing five distinct clusters. Mutation names are shown adjacent to the clustering plot. **(B)** Box-plot distributions of the normalized PRO mutation frequencies. Box-plots are color-coded using a rainbow scheme to visually distinguish the five PRO mutation frequency clusters.

https://doi.org/10.1371/journal.pone.0177452.g004

Discussion

Functional implications of the most common PRO and RT mutations

Previous research shows that the most common PRO mutation observed in the Puerto Rican sample–L63P –which is estimated to occur in half of drug-naïve patients, provides a strong adaptive benefit to HIV viruses replicating under drug pressure [20]. Indeed, the same PRO position 63 shows an array of amino acid substitutions that alter the site of the enzyme that is bound by antiretroviral drugs, thereby decreasing the drugs' affinity and efficacy [21]. The second most frequent PRO mutation that we observed in Puerto Rico–V77I –is considered to be

Fig 5. Trends in HIV-1 reverse transcriptase mutations in Puerto Rico from 2002 to 2011. (A) Normalized reverse transcriptase (RT) mutation frequencies, color-coded as shown in the key, are shown for the 2002–2011 period. White boxes indicate an absence of RT resistance mutations in any given year. RT mutation frequency profiles are grouped using hierarchical clustering, revealing five distinct clusters. Mutation names are shown adjacent to the clustering plot. **(B)** Box-plot distributions of the normalized RT mutation frequencies. Box-plots are color-coded using a rainbow scheme to visually distinguish the five RT mutation frequency clusters.

one of the most prominent non-active site mutations implicated in antiretroviral drug resistance. The V77I mutation facilitates increased drug resistance by providing conformational flexibility to the enzyme [22]. The third most abundant PRO mutation that we observed–I13V –is associated with fast virologic failure and decreased drug affinity [23]. Finally, M36I, a PRO mutation whose frequency remained relatively constant over the period of study, in both Puerto Rico and throughout Latin America, influences the flexibility of the protease and its complexed substrate, thereby mediating interactions linked to increased drug resistance [24, 25].

The most prevalent RT mutations observed in Puerto Rico during the 10-year period of this study were also the dominant mutations identified in a meta-analysis of HIV drug resistance trends in Latin America and the Caribbean between 2000 and 2015 [25]; it should be noted that the dataset used for the meta-analysis is distinct from the UCC mutation dataset that we analyzed here. The predominant RT mutation observed in this study–M184V –is widely

considered to be the most critical mutation with respect to resistance to multiple nucleoside and nucleotide analog RT inhibitors (NRTIs) [26, 27]. The presence of K103N, the second most common RT mutation that we observed, diminishes the efficacy of non-nucleoside analog RT inhibitors (NNRTIs) and, unlike other NNRTI-resistance mutations, persists for a prolonged period of time after the initial viral infection [27]. The third most common RT mutation that we observed–M41L –also confers resistance to NRTIs by helping to restore DNA polymerase activity to RT proteins that have been disabled by other mutations [28].

## Potential sources of bias in the observed drug resistance trends

Our study is dependent upon the results generated by the TRUGENE HIV-1 Genotyping Kit and OpenGene DNA sequencing system, which relies on a proprietary interpretative algorithm to generate the output that was used for the statistical analyses that we report. It is important to note that the accuracy of this system has been independently confirmed several times [29–31], including as part of a rigorous FDA approval process [32]. Nevertheless, the propriety software used by the TRUGENE kit was updated 6 times between 2002 and 2011, primarily in an effort to reflect the most current knowledge of HIV-1 gene mutation to drug resistance associations. These updates, together with any changes made in clinical practice, could introduce technical artifacts that may appear as dynamic trends based on the statistical analyses that we used to analyze HIV mutations and their associated drug resistance frequencies over time.

In an effort to evaluate this possible bias, we compared the results obtained from our statistical analyses with data published by the International Antiretroviral Society (IAS) for 2001 to 2012, which associate HIV mutations with resistance to specific antiretroviral drugs [33–43]. According to the IAS tables published from 2001 to 2004, the most frequent mutation that we observed for the RT gene–M184V –confers resistance to Zalcitabine, which also appears as the most frequent drug resistance in our analysis (Fig 3). The IAS data also associates M184V with the antiretrovirals Didanosine and Lamivudine, which were the second and third most frequent medications observed for our samples. These consistencies provide an additional line of support for the TRUGENE HIV-1 Genotyping Kit that we used. On the other hand, Zalcitabine was removed from the market in 2006, which explains why it disappears completely from our data after 2007, even though it could be inferred from Fig 3 that no resistance was observed for this medication in the last years of the study. Thus, missing mutation and/or resistance data from our study should be interpreted with some caution.

The same IAS data reveal several other potentially confounding factors regarding HIV-1 mutation-to-drug resistance associations that we studied. For example, the antiretrovirals Indinavir, Saquinavir and Ritonavir are listed individually from 2001 to 2005, but are shown in combination thereafter: Indinavir/ritonavir and Saquinavir/ritonavir. This change was made in response to the introduction of drug combinations to the market, which reduced pill burden while maintaining safe and effective viral control [44]. Tipranavir is absent from our analysis prior to 2006 because it was approved in 2005. Finally, Delavirdine was no longer recommended as part of an initial therapy regime from 2006, owing to its inconvenient dose schedule and lower efficacy when compared with other medications [45]; this explains its sudden decline in frequency observed for the last years of our study.

Conclusions

HIV-1 mutation and drug resistance trends in Puerto Rico were found to be highly dynamic over the 10-year period of the study. For both women and men, a marked decrease was seen for overall drug resistance and for protease mutations in particular, with the sharpest decline

Fig 6. Average number of drug resistance or mutations per individual during the 2002 to 2011 period. Values were computed for all individuals (black-solid), females (blue-dotted), and males (red-dashed).

occurring after 2006 (Fig 6). The reduced HIV-1 mutation and drug resistance trends that we observed are consistent with previous reports from multi-year cohort studies conducted around the world for the same time period [46–49]. Our results are also consistent with population genetic studies, which contend that the transition from early HIV drug therapies to the newer, more efficacious drug treatment regimes, including multi-drug cocktails, limited the ability of the virus to mutate and evolve drug resistance. Possible underlying reasons for the decline in HIV drug resistance include reduced viral load, the low probability of simultaneously evolving combinations of mutations to evade multiple drugs, more effective treatment guidelines and better treatment adherence [50, 51].

Interestingly, the prospect of selecting for resistant strains of HIV, along with elevated transmission rates of resistant virus in newly infected patients, were foreseen consequences of the broad implementation of HAART. On the other hand, our analyses concur with other studies that report declines in drug resistance following expansion of treatment, pointing to the ability of antiretroviral therapy to halt viral evolution [52, 53]. It has even been shown that the emergence of drug resistance can be virtually stopped when newer and more potent therapies are coupled with close patient monitoring [54]. These findings, considered together with the results of our own study reported here, underscore the critical importance of prospective cohort monitoring for combating the HIV/AIDS epidemic in Puerto Rico. Active surveillance of HIV-1 mutation and associated drug resistance trends are critical components that are needed to ensure the successful treatment of HIV infected patients on the island.

Supporting information

S1 Table. HIV-1 mutations and drug resistance in Puerto Rico from 2002 to 2011. A complete list of protease (PRO) mutations, reverse transcriptase (RT) mutations, and associated drug resistance, broken down by gender and year.
(XLSX)

Author Contributions

Conceptualization: LST LAC.

Data curation: LAC MLR LR IKJ.

Formal analysis: LR IKJ.

Funding acquisition: LAC.

Investigation: LST LAC ERO NB.

Methodology: LST LAC IKJ LR.

Project administration: LST LAC.

Resources: NB ERO IKJ LR.

Software: IKJ LR.

Supervision: LST LAC.

Validation: LAC IKJ.

Visualization: LST LR.

Writing – original draft: LST LAC IKJ LR.

Writing – review & editing: LST LR MLR ERO IKJ NB LAC.

References

1. Office of Epidemiological Research. Puerto Rico HIV/AIDS Surveillance Summary Cumulative HIV/AIDS Cases Diagnosed as of April 30, 2016. Puerto Rico Health Department; 2016 February 29, 2016. Report No.

2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2002. 2002.

3. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2011. 2011 February 2013. Report No.

4. Ulett KB, Willig JH, Lin HY, Routman JS, Abroms S, Allison J, et al. The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS. 2009; 23(1):41–9. PubMed Central PMCID: PMC2733237. https://doi.org/10.1089/apc.2008.0132 PMID: 19055408

5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493–505. PubMed Central PMCID: PMC3200068. https://doi.org/10.1056/NEJMoa1105243 PMID: 21767103

6. Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795–807. PubMed Central PMCID: PMC4569751. https://doi.org/10.1056/NEJMoa1506816 PMID: 26192873

7. Statistics NCfH. Health, United States, 2012: With Special Feature on Emergency Care. Hyattsville, MD: U.S. Department of Health and Human Services, 2013.

8. Centers for Disease Control and Prevention. Epidemiology of HIV infection through 2014. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, 2014.

9. Garcia D, Betancourt G, Scaccabarozzi L. The State of HIV/AIDS among Hispanics/Latinos in the US and Puerto Rico 2015. Available from: https://www.fpcouncil.com/sites/fpcouncil.com/files/files/HIVbrief2015_Eng.pdf.

10. Tossas-Milligan KY, Hunter-Mellado RF, Mayor AM, Fernandez-Santos DM, Dworkin MS. Late HIV Testing in a Cohort of HIV-Infected Patients in Puerto Rico. P R Health Sci J. 2016; 35(2):113–21. PMID: 27232874

11.   Chen NE, Gallant JE, Page KR. A systematic review of HIV/AIDS survival and delayed diagnosis among Hispanics in the United States. J Immigr Minor Health. 2012; 14(1):65–81. PubMed Central PMCID: PMC3329255. https://doi.org/10.1007/s10903-011-9497-y PMID: 21773882

12.   Sheehan DM, Trepka MJ, Dillon FR. Latinos in the United States on the HIV/AIDS care continuum by birth country/region: a systematic review of the literature. Int J STD AIDS. 2015; 26(1):1–12. PubMed Central PMCID: PMC4224994. https://doi.org/10.1177/0956462414532242 PMID: 24810215

13.   Puerto Rico Department of Health. Integrated epidemiological profile for HIV prevention in Puerto Rico, 2005–2011. 2012.

14.   Heron M. Deaths: Leading causes for 2008. Hyattsville, MD: National Center for Health Statistics, 2012.

15.   Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014; 312(4):410–25. https://doi.org/10.1001/jama.2014.8722 PMID: 25038359

16.   U.S. Department of Health & Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. U.S. Department of Health & Human Services, 2016.

17.   Cubano LA, Sepulveda-Torres Ldel C, Sosa G, Boukli N, Robles R, Rodriguez JW, et al. Prevalence of drug resistance and associated mutations in HIV-positive Puerto Ricans: sex variations. Ethn Dis. 2008; 18(2 Suppl 2):S2-132-6. Epub 2008/07/23.

18.   Cubano LA, Cumba L, del Sepulveda-Torres LC, Boukli N, Rios-Olivares E. Prevalence of drug resistance and associated mutations in a population of Hiv-1+ Puerto Ricans in 2005. Bol Asoc Med P R. 2010; 102(3):13–7. PubMed Central PMCID: PMC4556367. PMID: 23875516

19.   Sepulveda-Torres Ldel C, De La Rosa A, Cumba L, Boukli N, Rios-Olivares E, Cubano LA. Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006–2010. AIDS Res Treat. 2012; 2012:934041. PubMed Central PMCID: PMC3347695. https://doi.org/10.1155/2012/934041 PMID: 22593823

20.   Ammaranond P, Sanguansittianan S. Mechanism of HIV antiretroviral drugs progress toward drug resistance. Fundam Clin Pharmacol. 2012; 26(1):146–61. https://doi.org/10.1111/j.1472-8206.2011.01009.x PMID: 22118474

21.   Langs-Barlow A, Paintsil E. Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes. Viruses. 2014; 6(10):3855–72. PubMed Central PMCID: PMCPMC4213566. https://doi.org/10.3390/v6103855 PMID: 25333465

22.   Gupta A, Jamal S, Goyal S, Jain R, Wahi D, Grover A. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease. BMC Bioinformatics. 2015; 16 Suppl 19:S10. PubMed Central PMCID: PMCPMC4686784.

23.   Alteri C, Artese A, Beheydt G, Santoro MM, Costa G, Parrotta L, et al. Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. J Antimicrob Chemother. 2013; 68(10):2205–9. https://doi.org/10.1093/jac/dkt173 PMID: 23687186

24.   Costa MG, Benetti-Barbosa TG, Desdouits N, Blondel A, Bisch PM, Pascutti PG, et al. Impact of M36I polymorphism on the interaction of HIV-1 protease with its substrates: insights from molecular dynamics. BMC Genomics. 2014; 15 Suppl 7:S5. PubMed Central PMCID: PMCPMC4243740.

25.   Avila-Rios S, Sued O, Rhee SY, Shafer RW, Reyes-Teran G, Ravasi G. Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(6):e0158560. PubMed Central PMCID: PMCPMC4927069. https://doi.org/10.1371/journal.pone.0158560 PMID: 27355626

26.   Wensing AM, Calvez V, nthard HF, Johnson VA, Paredes R, Pillay D, et al. 2017 Update of the Drug Resistance Mutations in HIV-1. Topics in Antiviral Medicine. 2017; 24(4):Epub ahead of print.

27.   Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012; 72(9):e1–25. PubMed Central PMCID: PMCPMC3689909. https://doi.org/10.2165/11633630-000000000-00000 PMID: 22686620

28.   Boyer PL, Das K, Arnold E, Hughes SH. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase. Antimicrob Agents Chemother. 2015; 59(12):7184–96. PubMed Central PMCID: PMCPMC4649230. https://doi.org/10.1128/AAC.05069-14 PMID: 26324274

29.   Gale HB, Kan VL, Shinol RC. Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter. Clin Vaccine Immunol. 2006; 13(2):235–8. PubMed Central PMCID: PMCPMC1391930. https://doi.org/10.1128/CVI.13.2.235-238.2006 PMID: 16467331

30.   Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, et al. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol.

2003; 41(4):1594–9. PubMed Central PMCID: PMCPMC153857. https://doi.org/10.1128/JCM.41.4.1594-1599.2003 PMID: 12682150

31. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol. 2003; 41(4):1586–93. PubMed Central PMCID: PMCPMC153856. https://doi.org/10.1128/JCM.41.4.1586-1593.2003 PMID: 12682149

32. FDA. TRUGENE® HIV-1 Genotyping Kit and OpenGene® DNA Sequencing System: BK120013 2012. Available from: https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/SubstantiallyEquivalent510kDeviceInformation/ucm300085.htm.

33. D'Aquila R, Shapiro J, Brun-Vézinet F, Clotet B, Conway B, Grant R, et al. Update on Drug Resistance Mutations in HIV-1. Topics in Antiviral Medicine. 2001; 9(6):21–3.

34. D'Aquila RT, International AS-USA, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, et al. Drug Resistance Mutations in HIV-1. Top HIV Med. 2002; 10(5):21–5. PMID: 12717052

35. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003; 11(3):92–6. PMID: 12837968

36. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med. 2004; 12(4):119–24. PMID: 15516709

37. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med. 2005; 13(1):51–7. PMID: 15849371

38. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006; 14(3):125–30. PMID: 16946457

39. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007; 15(4):119–25. PMID: 17720996

40. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008; 16(1):62–8. PMID: 18441382

41. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009; 17(5):138–45. PMID: 20068260

42. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010; 18(5):156–63. Epub 2011/01/20. PMID: 21245516

43. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011; 19(4):156–64. PMID: 22156218

44. O'Brien WA 3rd. Saquinavir/Ritonavir: its evolution and current treatment role. AIDS Read. 2006; 16 (1):38–44; discussion 3. PMID: 16433471

45. U.S. Department of Health & Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. U.S. Department of Health & Human Services, 2006.

46. De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, et al. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 2013; 207 (8):1216–20. https://doi.org/10.1093/infdis/jit017 PMID: 23315324

47. Charest H, Doualla-Bell F, Cantin R, Murphy DG, Lemieux L, Brenner B, et al. A significant reduction in the frequency of HIV-1 drug resistance in Quebec from 2001 to 2011 is associated with a decrease in the monitored viral load. PLoS One. 2014; 9(10):e109420. PubMed Central PMCID: PMCPMC4190276. https://doi.org/10.1371/journal.pone.0109420 PMID: 25295725

48. Franzetti M, Violin M, Antinori A, De Luca A, Ceccherini-Silberstein F, Gianotti N, et al. Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003–2012 decade in Italy. BMC Infect Dis. 2014; 14:398. PubMed Central PMCID: PMCPMC4223427. https://doi.org/10.1186/1471-2334-14-398 PMID: 25037229

49. Duani H, Aleixo AW, Tupinambas U. Trends and predictors of HIV-1 acquired drug resistance in Minas Gerais, Brazil: 2002–2012. Braz J Infect Dis. 2016.

50. Pennings PS, Kryazhimskiy S, Wakeley J. Loss and recovery of genetic diversity in adapting populations of HIV. PLoS Genet. 2014; 10(1):e1004000. PubMed Central PMCID: PMCPMC3900388. https://doi.org/10.1371/journal.pgen.1004000 PMID: 24465214

51. Feder AF, Rhee SY, Holmes SP, Shafer RW, Petrov DA, Pennings PS. More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1. Elife. 2016; 5. PubMed Central PMCID: PMCPMC4764592.

52. Siliciano JD, Siliciano RF. Recent trends in HIV-1 drug resistance. Curr Opin Virol. 2013; 3(5):487–94. PubMed Central PMCID: PMCPMC3963152. https://doi.org/10.1016/j.coviro.2013.08.007 PMID: 24021560

53. Richman DD. Editorial Commentary: HIV Is Putting Up Less Resistance. Clin Infect Dis. 2016; 62 (10):1318–9. https://doi.org/10.1093/cid/ciw130 PMID: 26962077

54. Scherrer AU, von Wyl V, Yang WL, Kouyos RD, Boni J, Yerly S, et al. Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clin Infect Dis. 2016; 62(10):1310–7. https://doi.org/10.1093/cid/ciw128 PMID: 26962075